箕星是一家总部位于中国上海的生物制药公司，致力于将创新科学和药物带给罹患严重危及生命健康疾病的中国患者。箕星由RTW Investments, LP于2019年投资创立，与全球多家生物技术公司开展合作，通过开发和商业化独特创新的治疗药物，应对心血管和眼科疾病领域尚未满足的医疗需求。凭借强劲且不断壮大的产品管线、经验丰富的管理团队和以患者为中心的理念，箕星将为中国患者群体带来持久而深远的影响。更多信息，请访问 www.jixing.com<\/a>。<\/p> \n

\n \n \n \n \n \n \n \n
*Lee J, Schotzinger J, et al. The Selective Aldosterone Synthase Inhibitor PB6440 Normalizes Blood Pressure In A Human Aldosterone Synthase-Transgenic Mouse Model Of Hypertension, Hypertension 2022<\/b>, 79<\/i>, <\/i>A121. <\/i><\/span><\/p> <\/td> \n <\/tr> \n
*Pitt B, Bhatt D, et al, Inhibition Of Aldosterone Synthesis In Non-human Primates By PB6440, The Novel Highly Selective And Potent CYP11B2 Inhibitor, Hypertension 2020<\/b>, 76, AP233.<\/i><\/span><\/p> <\/td> \n <\/tr> \n
*NCD Risk Factor Collaboration (NCD-RisC), Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants, The Lancet 2021<\/b>, 398, 10304, 957-980.<\/i><\/span><\/p> <\/td> \n <\/tr> \n
*国家心血管病中心<\/i>, <\/i>中国医师协会<\/i>, <\/i>中国医师协会高血压专业委员会等<\/i>. <\/i>中国高血压临床实践指南<\/i>[J]. <\/i>中华心血管病杂志<\/i>, 2022<\/b>, 50(11): 1050-1095. DOI: 10.3760\/cma.j.cn112148-20220809-00613.<\/i><\/span><\/p> <\/td> \n <\/tr> \n
*Wang Z, Chen Z, Zhang L, et al. Status of Hypertension in China: results from the China hypertension survey, 2012– 2015. Circulation 2018<\/b>; 137: 2344–2356.<\/i><\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p>"]; $("#dvExtra").html(content_array[0]);})();